A5067359287- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pancreatic function and diabetes
- Diet and metabolism studies
- Pharmacology and Obesity Treatment
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cardiovascular Function and Risk Factors
- Pancreatitis Pathology and Treatment
- Neuropeptides and Animal Physiology
- Regulation of Appetite and Obesity
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal motility and disorders
- Gastroesophageal reflux and treatments
- Gastric Cancer Management and Outcomes
- Heart Failure Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic and Hepatic Oncology Research
- Heart Rate Variability and Autonomic Control
- Diet, Metabolism, and Disease
- Adipose Tissue and Metabolism
- Liver Disease Diagnosis and Treatment
St. Josef-Hospital
2016-2025
Katholisches Klinikum Bochum
2019-2025
Ruhr University Bochum
2016-2025
Universitätsmedizin Greifswald
2011-2025
The University of Adelaide
2025
Diabeteszentrum Bad Lauterberg
2013-2023
Novo Nordisk (Denmark)
2008-2019
Toronto Public Health
2017-2019
Indianapolis Zoo
2013-2019
University Hospitals of the Ruhr-University of Bochum
2017-2018
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.In this double-blind trial, we randomly assigned diabetes and high risk receive liraglutide or placebo. primary composite outcome the time-to-event analysis was first occurrence death from causes, nonfatal myocardial infarction, stroke. hypothesis that would be noninferior placebo regard outcome, margin 1.30 for upper boundary 95%...
In 2012, the American Diabetes Association (ADA) and European for Study of (EASD) published a position statement on management hyperglycemia in patients with type 2 diabetes (1,2). This was needed because an increasing array antihyperglycemic drugs growing uncertainty regarding their proper selection sequence. Because paucity comparative effectiveness research long-term treatment outcomes many these medications, 2012 publication less prescriptive than prior consensus reports. We previously...
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous hormones (gastric inhibitory peptide [GIP] and glucagon-like 1 [GLP-1] [7-36 amide]) in nine diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) age- weight-matched normal subjects. Synthetic human GIP (0.8 2.4 pmol/kg.min over h each), GLP-1 amide] (0.4 1.2 placebo were administered under hyperglycemic clamp...
OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition placebo or glimepiride in subjects previously treated oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, double-blind, double-dummy, placebo- active-controlled, parallel-group trial, 1,091 randomly assigned (2:2:2:1:2) once-daily (either 0.6, 1.2, 1.8 mg/day injected subcutaneously), placebo, (4 mg once daily). All treatments...
Integrated insulin secretion rates calculated from peripheral venous C-peptide measurements by two-compartment kinetic analysis were measured in six young normal subjects after increasing oral glucose loads of 25, 50, and 100 g respective isoglycemic infusions. The differences B-cell secretory responses between iv challenges attributed to factors other than glycemia itself (incretin effect). Both concentrations as well integrated increased with loads. Due the similarity profiles all loads,...
Glucagon-like peptide 1 (GLP-1) has been shown to inhibit gastric emptying of liquid meals in type 2 diabetic patients. It was the aim present study compare action physiological and pharmacological doses intravenous GLP-1-(7—36) amide GLP-1-(7—37) on normal volunteers. Nine healthy subjects participated (26 ± 3 yr; body mass index 22.9 1.6 kg/m ; hemoglobin A 1C 5.0 0.2%) five experiments separate occasions after an overnight fast. nasogastric tube positioned for determination volume by use...
Aim: To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes inadequate glycaemic control [haemoglobin A 1c (HbA ) ≥ 6.5 ≤10%] on metformin monotherapy. Methods: After a dose titration/stabilization period (≥1500 mg/day), 1172 were randomized to addition 100 mg q.d. (N = 588) or 5 mg/day (uptitrated potential maximum 20 mg/day) 584) for 52 weeks. The primary analysis assessed whether was non‐inferior regarding HbA changes from baseline at Week using...
Glucagon-like peptide 1 (GLP-1) and analogues are being evaluated as a new therapeutic principle for the treatment of type 2 diabetes. GLP-1 suppresses glucagon secretion, which could lead to disturbances hypoglycemia counterregulation. This has, however, not been tested.
OBJECTIVE Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent insulin may cause fewer these adverse effects. We compared the efficacy, safety, tolerability dapagliflozin sulfonylurea glipizide in patients type diabetes inadequately controlled metformin monotherapy....
Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1-(7-36) amide (GLP-1) are glucose-dependent insulinotropic gut hormones that may explain the greater insulin secretory response with oral compared to i.v. glucose (incretin effect). To study their individual combined contributions, in eight healthy volunteers, on separate occasions, synthetic human GIP (1 pmol/kg.min) and/or GLP-1 (0.3 or placebo were infused (-30 120 min), while at 0 min, a infusion "isoglycemic" profile after...